To compare vitreous concentrations of triamcinolone acetonide (TA) achieved by prior therapeutic intravitreal and subtenon injections. Interventional case ser ies. Vitreous samples were collected from patients who req...To compare vitreous concentrations of triamcinolone acetonide (TA) achieved by prior therapeutic intravitreal and subtenon injections. Interventional case ser ies. Vitreous samples were collected from patients who required vitreous surgery , six having received a subtenon injection of TA and another six, an intravitrea l injection. Vitreous concentrations of TA were measured by high-performance li quid chromatography. Vitreous concentrations of TA after intravitreal injection were 1.22 ±.0.24 μg/ml, significantly higher than those after subtenon injecti on ( < 0.001 μg/ml, P=0.003). Vitreous concentrations of TA after subtenon inje ction and TA-assisted vitrectomy performed in a few patients to visualize the t ransparent vitreous gel were 0.20 ±0.11 μg/ml, an intermediate amount between these two groups. Much higher vitreous concentrations of TA after intravitreal i njection than subtenon injection may accelerate therapeutic effect when intravit real injections are given to reduce macular edema. Subtenon injections of TA may act via the sclera as opposed to the vitreous.展开更多
文摘To compare vitreous concentrations of triamcinolone acetonide (TA) achieved by prior therapeutic intravitreal and subtenon injections. Interventional case ser ies. Vitreous samples were collected from patients who required vitreous surgery , six having received a subtenon injection of TA and another six, an intravitrea l injection. Vitreous concentrations of TA were measured by high-performance li quid chromatography. Vitreous concentrations of TA after intravitreal injection were 1.22 ±.0.24 μg/ml, significantly higher than those after subtenon injecti on ( < 0.001 μg/ml, P=0.003). Vitreous concentrations of TA after subtenon inje ction and TA-assisted vitrectomy performed in a few patients to visualize the t ransparent vitreous gel were 0.20 ±0.11 μg/ml, an intermediate amount between these two groups. Much higher vitreous concentrations of TA after intravitreal i njection than subtenon injection may accelerate therapeutic effect when intravit real injections are given to reduce macular edema. Subtenon injections of TA may act via the sclera as opposed to the vitreous.
